Co Diagnostics Stock Analysis
CODX Stock | USD 1.01 0.05 4.72% |
Co Diagnostics is undervalued with Real Value of 1.25 and Target Price of 2.0. The main objective of Co Diagnostics stock analysis is to determine its intrinsic value, which is an estimate of what Co Diagnostics is worth, separate from its market price. There are two main types of Co Diagnostics' stock analysis: fundamental analysis and technical analysis.
The Co Diagnostics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Co Diagnostics is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. CODX Stock trading window is adjusted to America/New York timezone.
CODX |
CODX Stock Analysis Notes
About 14.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.51. Some equities with similar Price to Book (P/B) outperform the market in the long run. Co Diagnostics recorded a loss per share of 1.38. The entity had not issued any dividends in recent years. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people. For more info on Co Diagnostics please contact Dwight Egan at (801) 438-1036 or go to https://www.codiagnostics.com.Co Diagnostics Investment Alerts
Co Diagnostics generated a negative expected return over the last 90 days | |
Co Diagnostics has some characteristics of a very speculative penny stock | |
Co Diagnostics has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 6.81 M. Net Loss for the year was (35.33 M) with profit before overhead, payroll, taxes, and interest of 28.74 M. | |
Co Diagnostics currently holds about 86.49 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Co Diagnostics has a poor financial position based on the latest SEC disclosures | |
Latest headline from thelincolnianonline.com: Co-Diagnostics Given Neutral Rating at HC Wainwright |
Co Diagnostics Upcoming and Recent Events
Earnings reports are used by Co Diagnostics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
21st of March 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
21st of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
CODX Largest EPS Surprises
Earnings surprises can significantly impact Co Diagnostics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2019-05-14 | 2019-03-31 | -0.08 | -0.09 | -0.01 | 12 | ||
2018-12-31 | 2018-12-31 | -0.13 | -0.15 | -0.02 | 15 | ||
2019-11-12 | 2019-09-30 | -0.07 | -0.1 | -0.03 | 42 |
CODX Stock Institutional Investors
Shares | Northern Trust Corp | 2024-09-30 | 55 K | Thompson Davis & Co Inc | 2024-09-30 | 41.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 40.4 K | Uma Financial Services Inc | 2024-06-30 | 31.4 K | Smi Advisory Services Llc | 2024-06-30 | 28 K | Virtu Financial Llc | 2024-06-30 | 27.9 K | Group One Trading, Lp | 2024-06-30 | 26.4 K | Citadel Advisors Llc | 2024-09-30 | 25.4 K | Ubs Group Ag | 2024-06-30 | 22.5 K | Vanguard Group Inc | 2024-09-30 | 1.8 M | Renaissance Technologies Corp | 2024-09-30 | 567.7 K |
CODX Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.25 M.CODX Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.51) | (0.54) | |
Return On Capital Employed | (0.48) | (0.45) | |
Return On Assets | (0.37) | (0.39) | |
Return On Equity | (0.41) | (0.43) |
Management Efficiency
Co Diagnostics has return on total asset (ROA) of (0.2761) % which means that it has lost $0.2761 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5057) %, meaning that it created substantial loss on money invested by shareholders. Co Diagnostics' management efficiency ratios could be used to measure how well Co Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to rise to -0.45 in 2024. At this time, Co Diagnostics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.8 M in 2024, whereas Total Assets are likely to drop slightly above 50.6 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.93 | 3.08 | |
Tangible Book Value Per Share | 2.03 | 2.13 | |
Enterprise Value Over EBITDA | (0.65) | (0.69) | |
Price Book Value Ratio | 0.45 | 0.43 | |
Enterprise Value Multiple | (0.65) | (0.69) | |
Price Fair Value | 0.45 | 0.43 | |
Enterprise Value | 27.1 M | 25.7 M |
Management at Co Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Operating Margin (15.96) | Beta (0.85) | Return On Assets (0.28) | Return On Equity (0.51) |
Technical Drivers
As of the 25th of November, Co Diagnostics owns the Information Ratio of (0.19), market risk adjusted performance of (0.61), and Variance of 14.46. Co Diagnostics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.Co Diagnostics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Co Diagnostics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Co Diagnostics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Co Diagnostics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Co Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Co Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Co Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Co Diagnostics Outstanding Bonds
Co Diagnostics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Co Diagnostics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CODX bonds can be classified according to their maturity, which is the date when Co Diagnostics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
CNO 165 06 JAN 25 Corp BondUS18977W2B58 | View | |
CNO 175 07 OCT 26 Corp BondUS18977W2A75 | View | |
CNO 265 06 JAN 29 Corp BondUS18977W2C32 | View | |
COACH INC 425 Corp BondUS189754AA23 | View | |
US189754AC88 Corp BondUS189754AC88 | View | |
MGM Resorts International Corp BondUS552953CD18 | View |
Co Diagnostics Predictive Daily Indicators
Co Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Co Diagnostics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Co Diagnostics Forecast Models
Co Diagnostics' time-series forecasting models are one of many Co Diagnostics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Co Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About CODX Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Co Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CODX shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Co Diagnostics. By using and applying CODX Stock analysis, traders can create a robust methodology for identifying CODX entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (5.59) | (5.87) | |
Operating Profit Margin | (6.27) | (6.58) | |
Net Loss | (5.19) | (5.45) | |
Gross Profit Margin | 0.39 | 0.40 |
Current CODX Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CODX analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CODX analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
2.0 | Hold | 1 | Odds |
Most CODX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand CODX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Co Diagnostics, talking to its executives and customers, or listening to CODX conference calls.
CODX Stock Analysis Indicators
Co Diagnostics stock analysis indicators help investors evaluate how Co Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Co Diagnostics shares will generate the highest return on investment. By understating and applying Co Diagnostics stock analysis, traders can identify Co Diagnostics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 23 M | |
Common Stock Shares Outstanding | 29.3 M | |
Total Stockholder Equity | 86 M | |
Tax Provision | -9.8 M | |
Quarterly Earnings Growth Y O Y | 0.308 | |
Property Plant And Equipment Net | 6 M | |
Cash And Short Term Investments | 58.5 M | |
Cash | 14.9 M | |
Accounts Payable | 1.5 M | |
Net Debt | -11.9 M | |
50 Day M A | 1.2108 | |
Total Current Liabilities | 5.7 M | |
Other Operating Expenses | 49.5 M | |
Non Current Assets Total | 33.2 M | |
Forward Price Earnings | 16 | |
Non Currrent Assets Other | -1.00 | |
Stock Based Compensation | 8.3 M |
Additional Tools for CODX Stock Analysis
When running Co Diagnostics' price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.